Changing aspirin use in patients with Type 2 diabetes in the UKPDS

Changing aspirin use in patients with Type 2 diabetes in the UKPDS

Item
http://www.wikidata.org/entity/Q28210884
Q28171627
sameAs
Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME EraGender, aging and longevity in humans: an update of an intriguing/neglected scenario paving the way to a gender-specific medicineType-II diabetes and pancreatic cancer: a meta-analysis of 36 studiesEvaluation of the uses of aspirin, statins and ACEIs/ARBs in a diabetes outpatient population in southern ThailandUse of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in SpainDifferences in cardiovascular disease risk factor management in primary care by sex of physician and patientGender differences in composite control of cardiovascular risk factors among patients with type 2 diabetes.Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.Sex-specific differential in risk of diabetes-related macrovascular outcomesThe association of angina pectoris with heart disease mortality among men and women by diabetes status: the Rancho Bernardo Study.Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.Diabetes as a risk factor for acute coronary syndrome in women compared with men: a meta-analysis, including 10 856 279 individuals and 106 703 acute coronary syndrome events.Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management.The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.Prescription of Aspirin for adults with Diabetes.Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke.The usefulness of antiplatelet prescriptions for the identification of patients with atherothrombosis in primary care: a Dutch cross-sectional study.
P2860

Changing aspirin use in patients with Type 2 diabetes in the UKPDS

Item
http://www.wikidata.org/entity/Q28210884
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@ast
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@en
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@nl
type
label
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@ast
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@en
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@nl
prefLabel
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@ast
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@en
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P407
P433
P478
P577
P698
P921
P3181
P356
P1433
P1476
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
@en
P2093
P2860
P304
P31
P3181
P356
10.1111/J.1464-5491.2004.01328.X
P407
P433
P478
P577
P698
P921